INTRODUCTION
Hairy cell leukemia (HCL) is a chronic lymphoproliferative disorder characterized by splenic and bone marrow infiltration, pancytopaenia and low numbers of circulating tumor B cells which show distinctive 'hair-like' cytoplasmic projections. The disease accounts for 2% of all lymphoid leukemias and is highly sensitive to therapeutic intervention using interferon-α or purine analogues (1) . The exact cell of origin of HCL remains unknown, but recent comparison of gene expression profiles of different B cell populations shows that HCL cells may be derived from either memory B-cells (2) or splenic B cells (3) . Despite the advances in diagnosis and treatment of HCL, pathogenic molecular events associated with the development of HCL are not well understood.
Cytogenetic analysis has shown that the most frequent chromosomal abnormalities of HCL cases include alterations of chromosome 5 (4), in particular band 5q13 (translocations, inversions and trisomies), and deletions of chromosome 7 (6) . The presence of trisomy 5 and disruption of 5q13 in HCL cases through translocations or inversions strongly suggests that a gene of oncogenic potential may be localized to this region.
Chromosomal translocations have facilitated positional cloning of disrupted disease-causing genes, and have been instrumental in studying the structure and mechanism of chromosomal rearrangements (7) (8) (9) . We have previously identified a HCL patient with a constitutional inversion, inv(5)(p13.1q13.3) (4) mapping to the same region frequently altered in sporadic HCL cases. During the search for candidate genes we mapped a number of genes, HCLG1 (10) , hEFG2 and HEXB (11) , on the telomeric side 4 of the 5q13.3 inversion breakpoint, none of which were found to be rearranged in sporadic HCL cases. HCLG1 encodes a TGF-beta inducible nuclear protein (10) and hEFG2 encodes a human mitochondrial elongation factor gene (11) . The betahexosaminodase (HEXB) gene encodes the beta element of dimeric hexosaminodase lysosomal enzymes, involved in the degradation of carbohydrate moieties of glycoproteins, glycolipids and proteoglycans (12) , and which are indispensable in human metabolism for the degradation of gangliosides, an essential class of outer-layer membrane lipids. The HEXB gene has previously been found to be frequently mutated in the genetic disorder Sandhoff disease, which is characterized by the accumulation of ganglioside GM2 in neuronal lysosomes, leading to severe and, in most cases, fatal neurodegeneration (13) .
The closest gene on the centromeric side of HEXB is the ectodermal neuronal cortex 1 ENC-1 gene. This gene has been shown to encode an F-actin associated protein, involved in differentiation of neural crest, colon and adipocyte cells (14) . In addition, upregulation of ENC-1 has been found in medulloblastoma (15) , prostate (16) , glioblastomas, astrocytomas (17) and colon cancer (18) tumors, indicating that it may function in an oncogenic manner if inappropriately expressed. Interestingly, the ENC-1 gene was originally cloned as a p53-induced gene (19) and the deduced Enc-1 protein contains a BTB/POZ domain and six KELCH repeats, a domain structure recently shown to associate with Cul3/4 SCF ubiquitin ligases (20) .
In this study, we report the cloning of the 5q13.3 and 5p13.1 breakpoints in a HCL patient with a constitutional inv 5 (p13.1q13.3) and demonstrate the disruption of a novel HEXB isoform, ENC-1AS, expressed as a cis-antisense transcript to the ENC-1 5 gene. Antisense transcripts have been found to be associated with a large number of mammalian genes, including N-MYC (21) , WT1 (22) , HOXA11 (23) , and LEU5/RFP2 (24) . Cis-acting antisense transcripts are often associated with a long (>100 bp) complementary sequences (25) and is increasingly recognized as an important regulatory mechanism affecting a variety of processes including RNA interference, translational repression, splicing, RNA transport and cytoplasmic stability, amongst others (26) (27) .
We show that the ENC-1 mRNA is significantly elevated in all 26 sporadic HCL patients examined, in contrast to the levels of ENC-1AS, and discuss further the potential role of ENC-1AS antisense expression and differential methylation in the regulation of ENC-1 expression. 
RESULTS
To map and clone the breakpoints in the HCL patient with the constitutional inv(5)(p13.1q13.3) a strategy that combined FISH, Southern blot hybridization, PCR and DNA sequencing was used. By FISH analysis, BAC clone CTC-347N9 covering the breakpoint at 5q13.3 was identified by separately hybridizing a series of overlapping BAC clones (see materials and methods) (Fig. 1A) . Using a set of probes designed from the CTC-347N9 sequence, Southern blot analysis identified a rearranged 3.3 kb PstI fragment using probe p3 ( Fig. 1B and 2B) . A PstI genomic library was constructed using DNA from the HCL patient with the inv(5). PCR analysis, using primers designed from the 3.3 kb fragment and vector specific primers, amplified the rearranged fragment which was sequenced and aligned to genomic sequence using the BLAST program. This analysis revealed that the inversion breakpoint juxtaposes the 5q13.3 sequence to genomic sequence present within BAC clone CTD-2196p11, which is located at 5p13.1.
This information allowed us to design primers in the vicinity of both the identified 5p13.1 and 5q13.3 breakpoint sequences, facilitating the amplification and cloning of the distal 5p13.1 inversion breakpoint. Finally, FISH analysis using BAC clones CTC-347N9 and CTD-2196p11 as probes on metaphase chromosomes confirmed the constitutional inv(5)(p13.1q13.3) (Fig. 1A) .
Two genes, ENC-1 (18, 28) and HEXB (29) , were localized in close proximity to the 5q breakpoint ( Fig. 2A) . ENC-1 encodes a protein with C-terminal kelch repeats and an N-terminal BTB/POZ domain. The ENC-1 gene is located only 18 kb centromeric to the 5q13.3 breakpoint, whereas the HEXB gene is located 26 kb telomeric of the breakpoint (Fig. 2B) . Telomeric of the HEXB gene, localized in a tail-to-tail arrangement, 7 is the mitochondrial elongation factor gene, hEFG2, previously cloned by us (11) . The availability of the orthologous mouse genomic sequence allowed us to examine the overall sequence conservation across the 5q13.3 breakpoint region in order to identify any possible conserved exons/elements in the 44 kb interval between the ENC-1 and HEXB genes. No conserved putative protein encoding domains were identified within this 44 kb segment despite extensive bioinformatic analysis including tblastx database search of the entire 44 kb segment against the Genbank nr database, nor could we identify conserved sequences of sufficient identity to indicate small protein encoding exons (30) .
However, the possibility still existed that additional untranslated exons or promoter/enhance/repressor element may exist for one or both of the genes flanking the 5q13.3 breakpoint. We therefore carried out detailed computer and database analysis of the breakpoint region in order to provide comprehensive transcriptional maps of the ENC-1 and HEXB genes. The ENC-1 gene contains three exons spanning 13,279 bp of genomic sequence (Fig. 2B) . In addition to the published mRNAs of 4827 bp (Genbank Accession number NM_003633) encoding a protein of 589 aminoacids (AA), the gene can be expressed in at least three alternative isoforms (Fig. 2B) . As previously described Expression of this alternative HEXB transcript was confirmed by both Northern and RT-PCR analysis in various tumor derived cell lines ( Fig. 4A and 5 ) and sequence analysis followed by BLAST2N alignments showed that the alternative 5' exon (Exon 1AS) is at least 541 bp in length and located 44,628 bp upstream of the previously described exon 1 ( Fig. 2b and Fig. 3 ) of HEXB. Importantly this novel alternative HEXB isoform spans the 5q13.3 inv(5) breakpoint and is therefore directly disrupted by the inversion breakpoint in the HCL patient. Surprisingly, exon 1AS also overlaps in opposite orientation the first exon of ENC-1 by 252 bp in a cis-antisense fashion ( Fig. 2 and 3 ). Conceptual translation of this novel alternative isoform of HEXB does not result in an ORF containing any complete functional domain of HEXB, indicating it most likely functions as a non-coding transcript. We therefore termed this gene ENC-1AS (Fig. 2 and Fig.3 ) and the corresponding transcript has been submitted to GenBank under accession no AY643499.
Genomic sequence and RT-PCR analysis show that the ENC-1/ENC-1AS structure is conserved between human and mouse, with a murine mENC-1AS transcript also identified by RT-PCR analysis (data not shown).
Flanking the 5p breakpoint, we identified the genes encoding the leukemia inhibitory factor (LIF) and Oncostatin M (OSM) specific receptor subunits, LIFR (32) and OSMR (33) , respectively (Fig. 2C) . EST database searches, direct sequence comparison between human and mouse genomic sequences and RT-PCR analysis of computer predicted exons identified three novel 5' exons of the LIFR gene (exon 1, 2 and 4, GenBank Accession nos. AY35796, AY35797 and AY35799, respectively) (Fig. 2D ).
These novel LIFR exons localize this gene to 40 kb centromeric of the 5p13.1 breakpoint (Fig. 2C and D) and the OSMR gene to 200 kb telomeric of the breakpoint. During the search for novel exons at the centromeric side of the 5p13.1 breakpoint, a number of ESTs were found to exactly match the corresponding genomic sequence in the interval between the 5p13.1 breakpoint and the LIFR gene. RT-PCR analysis, using primers in the most 5' and 3' ESTs, followed by sequence analysis revealed that these different EST clones all belong to a single spliced transcript composed of at least 11 exons covering more 114 kb of genomic sequence (Fig. 2D) . Similar to the ENC-1AS transcript, this gene is also transcribed from the reverse strand and in the opposite orientation to the LIFR gene (Fig. 2D) . The most 5' exon of this transcript localises within intron 4 of the LIFR gene and also shows conservation at the genomic nucleotide level with an orthologous non-coding transcript in mouse (Genbank Accession number AK047630). BLAST2N alignment revealed that two exons from this novel mRNA directly overlap two LIFR exons (exons 1 and 4) in an antisense fashion and we therefore termed this gene, LIFRAS ( Fig. 2C and D) . The LIFRAS gene has been submitted to GenBank under accession numbers AY357600-AY357607. Translation of the LIFRAS gene revealed no clear ORFs within either this transcript or the corresponding mouse ortholog, strongly suggesting that like ENC1-AS, it is a putative non-coding RNA, rather than a protein-encoding gene. In addition no optimal Kozak sequence is present in either alternative 5' exons of the (Fig. 6B) . No ENC-1AS expression was found in normal B lymphocytes from the patient with the constitutional inv(5) or in the Burkitt Lymphoma cell line Daudi (Fig. 5) . To confirm the transcriptional overlap and co-expression of ENC-1 and ENC-1AS, we also performed strand specific RT-PCR for both these genes using cDNA synthesized from H82 and AA cells which express both transcripts ( (Fig. 3 and 7) which also do not express ENC-1 mRNA (Fig. 4 and data not shown). The methylation seen in these cell lines appears to be confined to a 1.2 kb region encompassing the overlapping ENC-1 exon 1 and ENC-1AS exon 1 region and the genomic sequence immediately upstream of ENC-1 exon 1 (Fig. 3 and Fig. 7) . No hypermethylation of the conserved putative ENC-1AS promoter region, located within intron 1 of ENC-1, 1497 bp downstream of the ENC-1 promoter region, was seen in either of the two Burkitt cell lines or in any of the HCL or normal B-cell samples ( Fig. 3 and Fig. 7 ). Interestingly partial methylation of one CLL sample was found within the fragment amplified by primer pair ENCPF4 -ENCPR4 that encompasses most of ENC1-AS exon 1. This is in contrast to the lack of methylation at this locus found in HCL, ALL and normal CD19 purified B-cells and the complete methylation seen in the cell line Daudi (Fig. 7) . Bisulphite sequence analysis indicated that the methylation of this fragment in Daudi is confined to the 3' region, resulting in a hypomethylation pattern within ENC-1 intron 1 in contrast to the hypermethylation found in the overlap region.
Bisulphite sequence analysis of fragments ENCPF2 -ENCPR2 and ENCPF8 -ENCPR8 also confirmed the restriction results that the hypermethylation is confined within the 1.2 kb segment shown in Fig. 3 although there is evidence of partial methylation within the latter fragment in Daudi (Fig. 7 , lane 19 and data not shown).
DISCUSSION
Genetic changes and molecular events associated with malignant transformation and tumor progression of HCL have eluded researchers to date. Chromosomal abnormalities such as trisomy of chromosome 5, translocations and inversions involving 5q13 are known to occur in HCL (4) yet no strong candidate gene, dysregulated in HCL, has been characterized to date at this genomic locus. In the present study, we have cloned and sequenced both breakpoints in a HCL patient with a constitutional inv (5) and Cyclin D1, all of which have previously been found highly expressed in HCL cases (38) (39) (40) . Dysregulation of the wnt/β-catenin pathway in HCL, including inappropriate expression of TCF4 target genes, is currently under investigation.
In studying further possible regulatory mechanisms affecting ENC-1 expression we identified a differentially methylated region, encompassing 1.2 kb of genomic sequence which includes the ENC-1 exon 1, ENC-1AS exon 1 overlap segment ( Fig. 3 and 7). In the case of ENC-1, we found that its 5' upstream promoter region was nonmethylated in all 21 HCL tumor cases tested, but methylated in two Burkitt lymphoma cell lines, a finding consistent with the expression of ENC-1 in these samples ( 
MATERIALS AND METHODS

Primary tumor material and cell lines
Leukemic cells were collected with informed consent and local ethical committee approval from 26 patients with sporadic HCL and non-malignant lymphocytes were obtained from healthy individuals. HCL tumor cells were collected from the spleen in all patients. The identification of a patient with a constitutional inv (5)(p13.1q13.3) has been reported previously (4) . Leukemic cells were purified as previously described (5) 
FISH analysis
Metaphase spreads were prepared using standard methodology and dual-color FISH was performed as previously described (10) . A series of overlapping BAC clones obtained from BACPAC resources http://bacpac.chori.org/, containing inserts from the 5q13 region were selected based on their map location from the UCSC database and separately hybridized to metaphase slides prepared from the patient with the constitutional inv (5)(p13.1q13.3). BAC clones CTC-347N9 and CTD-2196p11 (covering the 5q13.3 and 5p13.1 breakpoints respectively), were subsequently used for hybridizing interphase slides prepared from the HCL patients described above. Labelling of probes and hybridization conditions for FISH was performed as previously described (45) . Peripheral mononuclear blood cells from healthy donors and non-malignant cells from the patient with the constitutional inversion on chromosome 5 were analyzed in parallel.
Breakpoint cloning and library construction
Basic molecular biology procedures, such as isolation of DNA and Southern blots were performed as previously described (47, 48) . Cloning of the 5q13.3 and 5p13.1 breakpoints was essentially as previously described (48) . Briefly, a PstI library was constructed using DNA from the patient with the constitutional inv (5)(p13.1q13.3) and the 5q13.3 breakpoint was cloned by PCR with vector specific primers (pBluescript II, Stratagene, USA) in combination with primers designed from the sequence of a DNA probe (termed p3) that detects a 3.3 kb rearranged band on Southern blot (see Fig. 1B and   2 ). PCR products from these reactions were cloned into the pCRII-TopoTA vector (Invitrogen) and sequenced using vector specific primers. Sequence reactions were performed as previously described (11) . All primers used for breakpoint cloning are listed in Table 1 . All PCR analysis was performed with the Advantage 2 polymerase mix according to the manufacturer's instructions (Clontech, Palo Alto).
Northern hybridization and RT-PCR
Total RNA was extracted using the Trizol Reagent (Life Technologies) Table 1 .
Bisulphite treatment and methylation analysis
Bisulphite treatment, PCR, followed by restriction digestion and sequencing was used to determine the methylation status of both the ENC-1 and ENC-1AS genes in purified HCL-samples, cell lines and normal B-cell samples as previously described (46) .
Predicted conserved promoter regions were identified using the program Consite (http://mordor.cgb.ki.se/cgi-bin/CONSITE/consite?rm=t_input) and primers specific for bisulphite modified DNA were designed using the program Methprimer (http://www.ucsf.edu/urogene/methprimer/index1.html). Primers ENCPF2, ENCPR2, ENCPF4, ENCPR4, ENCPF6, ENC1MF, ENC1MR, ENCPF8 and ENCPR8 (see figure 3 and Table 2 ) were used to amplify segments encompassing over 2 kb of sequence covering the 5' exons and predicted promoter regions of the ENC-1/ENC-1AS locus.
Methylated samples could be identified by the presence of the recognitions sites for the restriction enzymes HpyCH4IV, Taq1 and Hha1 that recognize the CpG containing sequences ACGT, TCGA and GCGC respectively, in bisulphite modified genomic DNA.
In addition the methylation status at these positions was confirmed by either direct bisulphite sequence analysis of PCR fragments or of fragments subcloned into the pCRIITopoTA plasmid vector (Invitrogen). Table 1 
LEGENDS TO FIGURES
